← Media

WAKIX (pitolisant) is FDA-approved for excessive daytime sleepiness in children age 6 and older with narcolepsy. If your family is considering it, here is a practical overview of use, timing, and safety points.

What WAKIX is

WAKIX is a once-daily, non-stimulant medication. Response is not always immediate; some patients need several weeks, sometimes up to 8 weeks, for full benefit. Set expectations early and track daytime function as dose is adjusted.

How to take it

• Give once daily in the morning, soon after waking.
• Can be taken with or without food.
• Do not take more than once a day or later in the day.
• If a dose is missed, skip it and resume the next morning; do not double doses.
• Dose may involve more than one tablet depending on weight and prescription.

Before starting

Review full history before starting: allergies, heart/liver/kidney disease, all medications and supplements, and pregnancy status when relevant. WAKIX is not indicated in severe hepatic impairment.

Important safety information

QT prolongation: WAKIX can affect cardiac electrical activity. Report palpitations, fainting, or unexplained dizziness promptly.

Hormonal birth control: hormonal methods may be less reliable during treatment and for at least 21 days after stopping; discuss non-hormonal backup options.

Pregnancy: discuss pregnancy planning and registry options (1-800-833-7460) with the prescribing team.

Side effects: insomnia and headache are common in pediatric use; adults also report nausea and anxiety. This is not a complete side-effect list.

Pros and cons in practice

Pros: non-stimulant option, once-daily dosing, and potential steady improvement in alertness. Cons: delayed onset, drug-interaction and QT considerations, and limited pediatric indications (not approved under age 6, and not approved for cataplexy under age 18).

Bottom line

WAKIX can be a useful part of pediatric narcolepsy care, but it requires careful monitoring and realistic timelines. Use it exactly as prescribed and keep close follow-up with the treating clinician.

This is a summary for education. Dosing, safety, and suitability are determined by the prescribing clinician. For full prescribing information and the official patient guide, see WAKIX.com or the package insert. WAKIX is a registered trademark of Bioprojet Europe, Ltd.; Harmony Biosciences.

Educational content only; this is not personalized medical advice. If you have urgent symptoms, seek emergency care.